Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
Rakesh PopatSarah R BrownLouise FlanaganAndrew HallWalter GregoryBhuvan KishoreMatthew StreetlyHeather OakerveeKwee YongGordon CookEric LowJamie Cavenaghnull nullPublished in: British journal of haematology (2018)